Abstract:Significance Trafficking of T cells to tumors is critical for the success of immunotherapy. The success against solid cancers is not as effective as desired owing to limited efficacy in delivering a higher frequency of T cells to the tumor microenvironment. At this time, no useful methods are available to enhance T-cell infiltration in tumors in a short time. New methods that could enhance T-cell trafficking in tumors are urgently in need. Up to now, the role of platelets in limiting T-cell infiltration in tumors is a neglected phenomenon. In our study, for the first time, we proved that perfluorocarbon nanoparticles could promote intratumoral infiltration of T cells via platelet inhibition, resulting in enhanced anti–PD-L1 immunotherapy. Cancer immunotherapy can stimulate and enhance the ability of the immune system to recognize, arrest, and eliminate tumor cells. Immune checkpoint therapies (e.g., PD-1/PD-L1) have shown an unprecedented and durable clinical response rate in patients among various cancer types. However, a large fraction of patients still does not respond to these checkpoint inhibitors. The main cause of this phenomenon is the limited T-cell infiltration in tumors. Therefore, additional strategies to enhance T-cell trafficking into tumors are urgently needed to improve patients’ immune responses. In this study, we screened an array of perfluorocarbon compounds, reporting that albumin-based perfluorotributylamine nanoparticles (PFTBA@Alb) can effectively increase the permeability of tumor blood vessels, and no distinct side effects were found on normal blood vessels. After i.v. administration of PFTBA@Alb, the number of tumor-infiltrating CD8+ and CD4+ T cells showed an obvious rising trend. More important, a striking tumor inhibition rate, reaching nearly 90%, was observed when combining PFTBA@Alb with anti–PD-L1 antibody. These findings suggest that PFTBA@Alb can be regarded as an enhancer for anti–PD-L1 immunotherapy.

Perfluorotributylamine-Loaded Albumin Nanoparticles Downregulate Platelet-Derived TGFβ to Inhibit Tumor Metastasis

Targeted downregulation of HIF-1α for restraining circulating tumor microemboli mediated metastasis

Perfluorocarbon Nanoparticle-Mediated Platelet Inhibition Promotes Intratumoral Infiltration of T Cells and Boosts Immunotherapy.

Perfluorocarbon Nanoparticles Mediated Platelet Blocking Disrupt Vascular Barriers to Improve the Efficacy of Oxygen-Sensitive Antitumor Drugs.

Transferrin-Modified Carprofen Platinum(IV) Nanoparticles as Antimetastasis Agents with Tumor Targeting, Inflammation Inhibition, Epithelial-Mesenchymal Transition Suppression, and Immune Activation Properties

‘Adhesion and Release’ Nanoparticle-Mediated Efficient Inhibition of Platelet Activation Disrupts Endothelial Barriers for Enhanced Drug Delivery in Tumors

Nanoplateletsomes Restrain Metastatic Tumor Formation Through Decoy and Active Targeting in a Preclinical Mouse Model.

Tumor-Specific Silencing of Tissue Factor Suppresses Metastasis and Prevents Cancer-Associated Hypercoagulability.

Platelets promote primary hepatocellular carcinoma metastasis through TGF-β1-mediated cancer cell autophagy

Platelets Promote Breast Cancer Cell MCF-7 Metastasis by Direct Interaction: Surface Integrin Alpha 2 Beta 1-Contacting-mediated Activation of Wnt-beta-catenin Pathway

Activated platelets facilitate hematogenous metastasis of breast cancer by modulating the PDGFR-β/COX-2 axis

Inhibition of Platelet Function Using Liposomal Nanoparticles Blocks Tumor Metastasis.

Activated Platelets‐Targeting Micelles with Controlled Drug Release for Effective Treatment of Primary and Metastatic Triple Negative Breast Cancer

The role of tumor-platelet interplay and micro tumor thrombi during hematogenous tumor metastasis

Direct interaction of platelet with tumor cell aggravates hepatocellular carcinoma metastasis by activating TLR4/ADAM10/CX3cl1 axis

Simultaneous blockage of contextual TGF-β by cyto-pharmaceuticals to suppress breast cancer metastasis

T Cell-Mimicking Platelet-Drug Conjugates

Artificial nanoplatelet regulation of tumor immune microenvironment to inhibit post-surgical tumor recurrence and lung metastasis

The interaction of platelet-related factors with tumor cells promotes tumor metastasis

Drug Delivery: Activated Platelets‐Targeting Micelles with Controlled Drug Release for Effective Treatment of Primary and Metastatic Triple Negative Breast Cancer (Adv. Funct. Mater. 13/2019)

Abstract 1435: Myeloid TGF-β Signaling Regulates Platelet Factor 4 Expression That is Important in Host Immune Suppression and Tumor Metastasis.